AVOIVE GA [CE]
| Composition | Cross-linked HA (20mg/mL)+Lidocaine |
| Indications | Lips, Glabellar Lines, Periorbital Lines |
| Duration | 06–08 months |
| Needle Size | 27G / 29G |
| Packing Unit | 1mL x 1 Syringe |
| Cross-linking Rate | ●○○ |
AVOIVE NA [CE]
| Composition | Cross-linked HA (20mg/mL)+Lidocaine |
| Indications | Lips, Forehead, Nasolabial Folds |
| Duration | 10–12 months |
| Needle Size | 27G / 29G |
| Packing Unit | 1mL x 1 Syringe |
| Cross-linking Rate | ●●○ |
AVOIVE DA [CE]
| Composition | Cross-linked HA (20mg/mL)+Lidocaine |
| Indications | Nose, Cheeks, Chin |
| Duration | 12–14 months |
| Needle Size | 27G / 29G |
| Packing Unit | 1mL x 1 Syringe |
| Cross-linking Rate | ●●● |
AVOIVE GA [CE]
| Composition | Cross-linked HA+Lidocaine |
| Indications | Lips, Glabellar Lines, Periorbital Lines |
| Duration | 06–08 months |
| Needle Size | 27G / 29G |
| Packing Unit | 1mL x 1 Syringe |
| Cross-linking | ●○○ |
AVOIVE NA [CE]
| Composition | Cross-linked HA+Lidocaine |
| Indications | Lips, Forehead, Nasolabial Folds |
| Duration | 10–12 months |
| Needle Size | 27G / 29G |
| Packing Unit | 1mL x 1 Syringe |
| Cross-linking | ●●○ |
AVOIVE DA [CE]
| Composition | Cross-linked HA+Lidocaine |
| Indications | Nose, Cheeks, Chin |
| Duration | 12–14 months |
| Needle Size | 27G / 29G |
| Packing Unit | 1mL x 1 Syringe |
| Cross-linking | ●●● |
